Events Partner Content Cell and Gene Therapy Manufacturing Forum Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.
Partner Content Partner Content A Run Down of Keynote Sessions for Cell & Gene Therapy 2... Cell and Gene Therapy
Partner Content Partner Content Your Exclusive Invitation from the Chair for Cell & Gene... Cell & Gene Therapy 2018 - Chair Invitation
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
Partner Content Partner Content Exclusive Speaker Interview for SMI’s Inaugural Cell & G... Speaker Interview for Cell & Gene Therapy 2018
Partner Content Partner Content Explore the latest developments in ATMPs at Cell & Gene ... Cell & Gene Therapy 2018
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.